Stockscreener 앱 받기
71.21
0.85%
-0.61
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen - Chartmill
Campbell & CO Investment Adviser LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
CEO Moves: How liquid is Halozyme Therapeutics Inc stockJuly 2025 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Halozyme Therapeutics (BIT:1HALO) Price Target Increased by 14.97% to 68.41 - Nasdaq
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity - Chartmill
Does Takeda’s ENTYVIO ENHANZE Deal Reshape The Bull Case For Halozyme Therapeutics (HALO)? - Sahm
Japan's Takeda partners with Halozyme to continue advancing Vedolizumab with ENHANZE® drug-delivery technology - BioSpectrum Asia
Trading Systems Reacting to (HALO) Volatility - Stock Traders Daily
Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy - Indian Pharma Post
Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correction2025 Dividend Review & Breakout Confirmation Alerts - Улправда
How Halozyme’s ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Moran Wealth Management LLC Grows Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains - Yahoo Finance
HALO or AXSM: Which Is the Better Value Stock Right Now? - Yahoo Finance
Halozyme, Takeda in arrangement to use former's drug delivery tech in Entyvio - MSN
Cardinal Capital Management Purchases Shares of 17,768 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Cerity Partners LLC Cuts Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Allspring Global Investments Holdings LLC Has $2.11 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How supply chain issues affect Halozyme Therapeutics Inc. stockPortfolio Risk Report & Consistent Profit Alerts - ulpravda.ru
Will Halozyme Therapeutics Inc. stock see insider buyingDividend Hike & Verified Technical Signals - ulpravda.ru
Is Halozyme Therapeutics Inc. stock ready for breakout2025 Key Highlights & Growth Focused Entry Reports - ulpravda.ru
Can Halozyme Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Review & Daily Momentum Trading Reports - ulpravda.ru
TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
TD Cowen Raises Price Target for HALO to $90.00, Maintains Buy Rating | HALO Stock News - GuruFocus
TD Cowen raises Halozyme Therapeutics stock price target to $90 on growth outlook - Investing.com Canada
Halozyme Partners with Takeda to Develop and Commercialize Vedolizumab - Contract Pharma
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab - Nasdaq
Takeda (TAK) Partners with Halozyme for Enhanced Drug Delivery - GuruFocus
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech - Investing.com
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech By Investing.com - Investing.com Australia
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE - Chartmill
Why Halozyme Therapeutics Inc. stock remains undervaluedLarge Cap Stability Picks & Low Cost Capital Trading - Улправда
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 43% One-Year Surge? - Sahm
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Haloz - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (NASDAQ:HALO) Director Sells $140,500.00 in Stock - MarketBeat
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - marketscreener.com
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Robust Revenue Growth and Strategic Partnerships Fuel Investor Optimism - DirectorsTalk Interviews
Should Halozyme’s Upgraded 2025 Revenue and Profit Guidance Reshape Expectations For Halozyme Therapeutics (HALO) Investors? - Sahm
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology - Investing.com
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
Halozyme Therapeutics (FRA:RV7) EV-to-OCF : 14.00 (As of Jan. 04, 2026) - GuruFocus
Cwm LLC Acquires 22,813 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arbor Investment Advisors LLC Invests $1.32 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Valuation Update: Why Halozyme Therapeutics Inc RV7 stock is a must watch tickerJuly 2025 Rallies & Low Drawdown Trading Techniques - moha.gov.vn
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 - The Globe and Mail
4.73%
0.92%
자본화:
|
볼륨(24시간):